| Terminated | Study to Evaluate the Safety, Tolerability, and Efficacy of SRP-9004 Administered by Systemic Infusion in Limb NCT06747273 | Sarepta Therapeutics, Inc. | Phase 1 |
| Not Yet Recruiting | The Role of Muscle Ultrasound in Assessment of Sample of Patients With Limb-girdle Muscular Dystrophy NCT06399770 | Assiut University | — |
| Active Not Recruiting | Evolution of the Functional and Muscular State of Patients With Muscular Dystrophy 2A Belts NCT06390566 | Assistance Publique - Hôpitaux de Paris | — |
| Recruiting | LGMD R1 Natural History Study NCT05618080 | Virginia Commonwealth University | — |
| Active Not Recruiting | A Trial to Learn More About an Experimental Gene Therapy Called Bidridistrogene Xeboparvovec (SRP-9003) as a P NCT06246513 | Sarepta Therapeutics, Inc. | Phase 3 |
| Recruiting | Rehabilitation in Muscular Dystrophies From the Hospital Facility to the Home: Pilot Project [RIMUDI] NCT06378203 | IRCCS Eugenio Medea | N/A |
| Terminated | A Gene Transfer Study to Evaluate the Safety, Tolerability and Efficacy of SRP-6004 in Ambulatory Participants NCT05906251 | Sarepta Therapeutics, Inc. | Phase 1 |
| Recruiting | A Study to Evaluate the Safety of AB-1003 (Previously LION-101) in Subjects With Genetic Confirmation of LGMD2 NCT05230459 | AskBio Inc | Phase 1 / Phase 2 |
| Active Not Recruiting | A Gene Transfer Single Dose Study to Evaluate the Safety, Tolerability and Efficacy of SRP-9003 in Non-Ambulat NCT05876780 | Sarepta Therapeutics, Inc. | Phase 1 |
| Unknown | Schulze Muscular Dystrophy Ability Clinical Study NCT05409079 | AbiliTech Medical Inc. | N/A |
| Active Not Recruiting | A Study of the Natural History of Participants With LGMD2E/R4, LGMD2D/R3, LGMD2C/R5, and LGMD2A/R1 ≥ 4 Years o NCT04475926 | Sarepta Therapeutics, Inc. | — |
| Recruiting | MRI-phenotyping of Patients With Pathogenic Anoctamin 5 Variants NCT05102799 | Rigshospitalet, Denmark | — |
| Unknown | Limb-Girdle Muscular Dystrophy Type 2I in Norway NCT03930628 | University Hospital of North Norway | — |
| Completed | Biomarker Development in LGMD2i NCT04202627 | ML Bio Solutions, Inc. | — |
| Terminated | A Study of Deflazacort (Emflaza®) in Participants With Limb-Girdle Muscular Dystrophy 2I (LGMD2I) NCT03783923 | PTC Therapeutics | Phase 3 |
| Completed | Weekly Steroids in Muscular Dystrophy NCT04054375 | Northwestern University | Phase 2 |
| Completed | Defining Clinical Endpoints in Limb Girdle Muscular Dystrophy (LGMD) NCT03981289 | Virginia Commonwealth University | — |
| Active Not Recruiting | 3 Year Follow up on ANO5 Patients NCT05206617 | Rigshospitalet, Denmark | — |
| Completed | Study to Evaluate the Long-Term Safety, Tolerability, and Biological Activity of ATYR1940 in Participants With NCT02836418 | aTyr Pharma, Inc. | Phase 1 / Phase 2 |
| Completed | MRI on Persons With Mutations in POMT2 Gene (LGMD2N) NCT02759302 | Rigshospitalet, Denmark | — |
| Completed | MRI and Muscle Involvement in Patients With Mutations in GMPPB NCT02635321 | Rigshospitalet, Denmark | — |
| Unknown | Global FKRP Registry NCT04001595 | Newcastle University | — |
| Withdrawn | Cell Therapy in Limb Girdle Muscular Dystrophy NCT02245711 | Neurogen Brain and Spine Institute | Phase 1 |
| Completed | Cardiac Magnetic Resonance in Children With Muscular Dystrophy NCT01081080 | Cooperative International Neuromuscular Research Group | — |
| Completed | Clinical Trial of Coenzyme Q10 and Lisinopril in Muscular Dystrophies NCT01126697 | Cooperative International Neuromuscular Research Group | Phase 2 / Phase 3 |
| Completed | Cardiac Outcome Measures in Children With Muscular Dystrophy NCT01066455 | Cooperative International Neuromuscular Research Group | — |
| Recruiting | Congenital Muscle Disease Study of Patient and Family Reported Medical Information NCT01403402 | Cure CMD | — |
| Completed | Safety Study of Transvenous Limb Perfusion in Human Muscular Dystrophy NCT00873782 | University of North Carolina, Chapel Hill | Phase 1 |
| Withdrawn | Stem Cell Therapy in Limb Girdle Muscular Dystrophy NCT02050776 | Neurogen Brain and Spine Institute | Phase 1 |
| Completed | Genetic Characterization of Individuals With Limb Girdle Muscular Dystrophy NCT00457912 | Nationwide Children's Hospital | — |
| Completed | Study Evaluating MYO-029 in Adult Muscular Dystrophy NCT00104078 | Wyeth is now a wholly owned subsidiary of Pfizer | Phase 1 / Phase 2 |
| Recruiting | Molecular Analysis of Patients With Neuromuscular Disease NCT00390104 | Boston Children's Hospital | — |